OXFORD, UK, September 30th, 2013
PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30th September 2013.
NanoSight’s business is based upon its unique Nanoparticle Tracking Analysis (NTA) instrumentation and software technology and their application across life science and non-life science research. The acquisition follows exceptional year-on-year revenue growth for NanoSight with the company being named as one of 100 fastest growing tech companies in Britain in 2013.
This successful sale also builds on PharmaVentures reputation and success in the M&A field.
Fintan Walton, CEO, PharmaVentures Ltd said: “PharmaVentures is delighted to have worked with NanoSight to find the ideal acquirer who can take the company and its unique technology to next level.”
Adrian Dawkes, VP, who led the transaction team at PharmaVentures added: “This is a fantastic outcome for NanoSight as it will expand their presence in existing markets and give access to previously untapped regions via Malvern’s established presence and respected brand.”
Over the past 21 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.